X
    X
    X
    X

    Edwards Wildman's Trio Writes Article on How Generic Drug Companies Have Seized on Inter Partes Review Proceedings in Law360

    News
    Brian Murphy, an intellectual property partner in Edwards Wildman's New York office, Ralph Loren a partner in the firm's Boston office, and Christine Dudzik, a Chicago-based partner, wrote an article about how generic drug companies have seized on the U.S. Patent and Trademark Office’s inter partes review proceeding as a new weapon in their assault on patents protecting branded drug products in Law360. In the article, "A New Weapon In Generic Drug Companies' Arsenal," the authors discussed how brand-name drug companies, already facing stiff competition from generics, now face the prospect of fighting a two-front patent war — in the district court and in the USPTO.

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.